A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial.
In conclusion, TNFRSF14 may serve a tumor suppressive role in bladder cancer by inducing apoptosis and suppressing proliferation, and act as a novel prognostic biomarker for bladder cancer.
PMID: 30066919 [PubMed – as supplied by publisher]
DiscussionRapidArc has an obvious advantage in improving the degree of target coverage, improving organs at risk, sparing healthy tissue, and significantly reducing the treatment time. FDG-PET/CT can increase the agreement between biopsies and delineated tumor volume and has the potential to positively impact the course of treatment. The Comet assay is attractive as a potential clinical test of tumor radiosensitivity. During radiotherapy, accurately defining disease areas is critical to avoid the unnecessary irradiation of normal tissue. Based on FDG-PET/CT and Comet assay, higher doses can be safely delivered to accurate …
Human Gene Therapy, Ahead of Print.
Urinary bladder cancer is a common malignancy worldwide. Environmental factors and chronic inflammation are correlated with the disease risk. Diagnosis is performed by transurethral resection of the bladder, a…
We present three cases with pulmonary metastases from BML and discuss the pathogenesis and management of this rare condition.
BLADDER cancer symptoms are usually spotted by checking your urine after using the toilet. But what signs are you exactly looking out for? These are the most common bladder cancer symptoms, including finding blood in your wee.
History and clinical findings: A 87-year-old lady was admitted to the medical ward with urinary tract infection. It was noted to have sudden painful bleeding blisters in her lower legs of 1 week duration. She had a background of stage 4 chronic renal failure since 2009 and was diagnosed of urothelial bladder cancer in December 2015. She was on Bisoprolol, calcichew, folic acid, isosorbide mononitrate, zomorph, ranitidine, levothyroxine, buscopan and paracetamol. On examination there was a large 1 cm × 2 cm hemorrhagic blister on her left lower leg on background of multiple tender purpuric and necrotic plaques on both lower legs.
Authors: Stakišaitis D, Juknevičienė M, Ulys A, Žaliūnienė D, Stanislovaitienė D, Šepetienė R, Slavinska A, Sužiedėlis K, Lesauskaitė V
The aim of the present study was to assess the ABO blood group polymorphism association with prostate, bladder and kidney cancer, and longevity. The following data groups were analyzed: Prostate cancer (n=2,200), bladder cancer (n=1,530), renal cell cancer (n=2,650), oldest-old (n=166) and blood donors (n=994) groups. The data on the ABO blood type frequency and odds ratio in prostate cancer patients revealed a significantly higher blood group B frequency (P
To evaluate the accuracy of 11C-acetate Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) in bladder cancer (BC) staging and monitoring response to neoadjuvant chemotherapy (NAC).
Conditions: Infiltrating Bladder Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma; Stage III Bladder Urothelial Carcinoma Interventions: Drug: Gemcitabine Hydrochloride; Drug: Cisplatin; Biological: Pegfilgrastim; Procedure: Conventional Surgery; Procedure: Radical Cystectomy; Other: Chemoradiotherapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Not yet recruiting